Skip to main content
. 2022 Dec 21;14:182. doi: 10.1186/s13148-022-01402-8

Table 2.

Acetyltransferases involvement in disease outcomes

Name Target Disease References
MYST1 NFR2 Non-small-cell lung cancer [68]
EGFR Glioblastoma [48]
TGFβ Fibrosis [49]
Tip60 Neural plasticity genes Neuronal disease [69]
DNA repair genes Breast cancer [70]
MYST2 β-catenin Alzheimer’s disease [71]
MLLX Acute myeloid leukaemia [72]
MYST3 KAT6a/MYST3 Syndromic developmental delay [73]
MYST4 MAPK Noonan syndrome-like phenotype [52]
MYST4 OE High-grade serous carcinoma [75]
GCN5 GCN5 OE Hepatocellular carcinoma [76]
Egr-1, E2F1, Bim Brain injuries [76]
p300/CBP cAMP-PKA, p53, ER Lung cancer [123]
NAT10 CEP170 Multiple myeloma [60]
NatA β-catenin /cyclin D1, HIf1a, TSC2/mTOR, E-cadherin, p21, PIX/Cdc42/Rac1, MLCK, DNMT1 Cancer [79]
NatB Tropomyosin, CDK2, Hippo/YAP, ERK1/2 Hepatocellular carcinoma [84]
NatD Slug Lung cancer [67]
NatF INFα Influenza A virus [103]

The acetylated targets and the diseases related to compromised acetylation are reported